Results 101 to 110 of about 5,109,346 (334)
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
Cancer Cell International, 2019 Background Hepatocyte nuclear factor 4α (HNF4α) is a tissue-specific transcription factor that regulates the expression of numerous genes in hepatocytes and pancreatic β cells.
Qiqing Sun +9 more
doaj +1 more source
Gut, 2019 Background and aim The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation ...
M. Goggins +26 more
semanticscholar +1 more source
Cancer immunology research, 2020 Pancreatic cancer tends to be radioresistant, but the immune-mediated mechanisms behind this resistance are unclear. Lactate secretion from pancreatic tumor cells leads to immune-suppressive MDSCs via HIF-1α signaling in MDSCs, limiting radiotherapy ...
Xuguang Yang +11 more
semanticscholar +1 more source
Pancreatic Cancer: Surgery of pancreatic cancer
Annals of Oncology, 1994 Pancreatic cancer which has an increasing incidence in the western countries is associated with an especially poor prognosis. This is mainly due to the low proportion of early and radically resectable stages, when diagnosed. Patients with irresectable disease have a median survival time of 3-4 months and their prognosis is not essentially improved by ...
openaire +2 more sources
EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
Molecular Oncology, EarlyView.The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche +8 more
wiley +1 more source
Molecular Cancer, 2019 Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death and is one of the most difficult-to-treat cancers. Surgical resection and adjuvant therapy have limited effects on the overall survival of PDAC patients.
Xiaomeng Liu +8 more
doaj +1 more source
Molecular Oncology, EarlyView.A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul +11 more
wiley +1 more source
A case of duodenal hemorrhage due to arteriovenous malformation around a serous cystic neoplasm
Surgical Case Reports, 2018 Background No reports have so far described arteriovenous malformation (AVM) in the pancreas caused by a tumor. We herein report a case of pancreatoduodenectomy for a patient who developed duodenal hemorrhage due to AVM developed around serous cystic ...
Shunsuke Tamura +10 more
doaj +1 more source